How Does This Diagnostics Network Operate?
Labcorp Holdings is a diagnostics and laboratory testing business serving healthcare providers and patients. It runs a large testing network that processes routine and specialized lab work, alongside related clinical services. The company’s scale shows up in its broad footprint and high-volume processing model, where day-to-day execution and asset use matter. With a market value around USD 22.8 billion, it sits in the middle of the public healthcare services landscape.
Are Margins And Cash Flow Holding Steady?
FundamentalsFor 2025, reported in USD, revenue reached about USD 14.0 billion, growing 7.2% year over year, with EBIT at roughly USD 1.4 billion. Profitability remained consistent, with a 28.83% gross margin and a 10.18% operating margin over the trailing period.
Operating cash generation was supported by USD 681 million of depreciation and amortization against USD 435 million of capital spending, producing a cash flow proxy of about USD 1.4 billion. The balance sheet held USD 532 million of cash and USD 1.0 billion of total debt, while ROE over the trailing period was 10.91%.
Is The Stock Priced Below Fair Value?
DCF / MultiplesAt USD 277.74, the stock sits above the lower fair value estimate of USD 216.84, below the central estimate of USD 351.41, and well below the upper estimate of USD 508.49. That places the current price in the lower half of the valuation range, alongside a trailing P/E of 24.19 and EV/EBITDA of 16.34.
Moderate Returns Require Discipline
TakeawayThe valuation gives credit for better capital productivity over time. That requires returns to hold up while the business grows. If returns slip, the current price has less support. Debt and reinvestment discipline matter when returns are only moderate.